Johnson & Johnson (JNJ) will begin allowing new patients to enroll in a rationing program to receive the cancer drug Doxil because some of the limited, remaining supply has been freed up. In a notice posted on the Doxil website Wednesday, J&J said it will reopen enrollment in the program starting Friday because some prior requests from doctors have changed and freed up supplies. Some doctors told J&J that Doxil supplies earmarked for patients already enrolled were no longer needed or they opted patients out of the program, the company said.
